2018-13293. Novartis Pharmaceuticals Corporation, et al.; Withdrawal of Approval of Five New Drug Applications  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA or Agency) is withdrawing approval of five new drug applications (NDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

    DATES:

    Approval is withdrawn as of July 23, 2018.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The holders of the applications listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

    Application No.DrugApplicant
    NDA 020831Foradil Aerolizer (formoterol fumarate) Powder, 0.012 milligram (mg)/inhalationNovartis Pharmaceuticals Corp., One Health Pl., East Hanover, NJ 07936.
    NDA 022504Axiron (testosterone) Transdermal Metered Solution, 30 mg/1.5 milliliter (mL) actuationEli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285.
    NDA 050585Rocephin (ceftriaxone sodium) for Injection, equivalent to (EQ) 10 gram (g) base/vial, EQ 250 mg base/vial (IV/IM), EQ 500 mg base/vial (IV/IM), EQ 1 g base/vial (IV/IM), EQ 2 g base/vial (IV/IM), EQ 500 mg base/vial, N/A; N/A, 1% (Rocephin kit), EQ 1 g base/vial, N/A; N/A, 1% (Rocephin kit)Hoffmann-La Roche, Inc., c/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.
    NDA 050624Rocephin (ceftriaxone sodium) with Dextrose in Plastic Container Injection, EQ 10 mg base/mL, EQ 20 mg base/mL, and EQ 40 mg base/mLDo.
    NDA 202763Testosterone Gel, 25 mg/2.5 g packet, 50 mg/5 g packetANI Pharmaceuticals, Inc., 210 Main St. West, Baudette, MN 56623.
    Start Printed Page 28857

    Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of July 23, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on July 23, 2018 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

    Start Signature

    Dated: June 14, 2018.

    Leslie Kux,

    Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2018-13293 Filed 6-20-18; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
06/21/2018
Department:
Health and Human Services Department
Agency:
Food and Drug Administration
EntryType:
Notice
Action:
Notice.
Document Number:
2018-13293
Dates:
Approval is withdrawn as of July 23, 2018.
Pages:
28856-28857 (2 pages)
Docket Numbers:
Docket No. FDA-2018-N-2194
SectionNoes:
PDF File:
2018-13293.pdf